Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

Shanghai Junshi (1877 HK): 2025 Sail On Tuoyi Momentum, Losses Narrow, Pipeline Strengthen

Shanghai Junshi Bioscience (1877 HK): Turns Profitable in 1H26 on Steady Domestic Revenue of Tuoyi

Shanghai Junshi Bioscience (1877 HK): Tuoyi Holds Momentum Steady As a Rock, Losses Narrow in 1H

Shanghai Junshi Bioscience (1877 HK): Tuoyi Gains Momentum; Losses Narrow; New Geographies Open Up

Shanghai Junshi Bioscience (1877 HK): Placement Good, A Long Term Bet for Sure

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/shanghai-junshi-biosciences-co-838d3eb3-3e0d-45f0-a9c5-ab0764709221" target="_blank" data-smartkarma-citation="entities:27760:1" rel="noopener">Shanghai Junshi Biosciences (1877 HK)</a> announced preliminary results for 2025 reporting 28% revenue growth on the back of toripalimab in China, alongside further narrowing of losses.</li>
<li>The domestic sales revenue of the core product, Tuoyi, increased significantly by approximately 38% YoY to nearly RMB 2.1B.</li>
<li>The new drug application for Reconkibart injection (JS005) was accepted by NMPA. JS005 had achieved positive results in Phase 3 trials for the treatment of moderate to severe plaque psoriasis.</li>
</ul>



Shanghai Junshi Biosciences (1877 HK) announced preliminary results for 2025 reporting 28% revenue growth on the back of toripalimab in China, alongside further narrowing of losses.
The domestic sales revenue of the core product, Tuoyi, increased significantly by approximately 38% YoY to nearly RMB 2.1B.
The new drug application for Reconkibart injection (JS005) was accepted by NMPA. JS005 had achieved positive results in Phase 3 trials for the treatment of moderate to severe plaque psoriasis.


Shanghai Junshi (1877 HK): Preliminary 2025 Results Reflect Positive Tuoyi Impact, Losses Narrow